Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy

@article{Wenzel2012RenalPI,
  title={Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy},
  author={Ren{\'e} R. Wenzel},
  journal={Drugs},
  year={2012},
  volume={65},
  pages={29-39}
}
Hypertension is common in chronic renal disease and is a risk factor for the faster progression of renal damage, and reduction of blood pressure (BP) is an efficient way of preventing or slowing the progression of this damage. International guidelines recommend lowering BP to 140/90mm Hg or less in patients with uncomplicated hypertension, and to 130/80mm Hg or less for patients with diabetic or chronic renal disease. The attainment of these goals needs to be aggressively pursued with multidrug… 
Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications.
TLDR
The main aims of this review are to describe the genetic characteristics of RAS components and to identify the possible pharmacogenetic implications for RAS-blocker drugs in the hypertension-CKD scenario.
Endothelin Receptor Antagonists in Diabetic Nephropathy
TLDR
The three clinical trials with avosentan and atrasentan published so far show the unique nephroprotective effects of these drugs, with a reduction of up to 45 % in albuminuria, however, fluid retention, oedema and, in higher stages of chronic kidney disease, heart failure limit their use.
Effectiveness of antihypertensive drugs in hypertensive patients with end stage renal failure.
TLDR
The findings suggested better BP control with CCB-diuretic relative to other combinations used, except for CCB -diuretics and BB-CCB-alpha blocker.
Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats.
TLDR
The data suggest that angiotensin-converting enzyme-inhibitor attenuates the progression of renal damage the most in those individuals with decreased basal renal endothelial-mediated vasodilation.
Optimizing inhibition of the renin-angiotensin system in hypertension.
TLDR
An hypothesis was tested that a novel renin inhibitor, named VTP-27999 (Methyl N-[2-[(R)(3-Chlorophenyl)[(3R)-1-[[(2S)-2-(methylamino)-3-yl]propyl]amino]-3-piperidinyl]methoxy]ethyl]carbamate trifluoroacetate), was more potent than aliskiren at reducing renin activity.
Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis
TLDR
ARB had a favorable impact on BP and renal parameters such as proteinuria with monotherapy as well as with combination therapy, highlighting their potential benefits in patients with hypertension and CKD.
Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
TLDR
A meta-analysis of seven RCTs of BP lowering treatment for patients with hypertension and CKD found that ACEI/ARB + CCB had no additional renoprotective benefit beyond than what could be achieved with ACEi/ARB monotherapy.
The role of sympathetic nervous activity in renal injury and end-stage renal disease
TLDR
The purpose of this review is to provide an overview of the current knowledge on the relationships between sympathetic nerve activity and renal function to further the understanding of the precise roles of sympathetic nervous activity in renal injury, particularly in the context of obesity and hypertension.
Association of renal function with the ambulatory arterial stiffness index and pulse pressure in hypertensive patients
TLDR
AASI is more closely associated with eGFR compared with 24-h PP in hypertensive inpatients, however, for MA 24-H PP is a better predictor.
Hypertensive Notfälle und Nierenarterienstenose
TLDR
In patients with resistant hypertension and hypertensive emergencies, factors which commonly contribute to uncontrolled BP should be excluded; they comprise non-compliance and insufficient understanding of the patient, inadequate therapy, and common secondary causes of hypertension.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 87 REFERENCES
Renal protection and antihypertensive drugs: current status.
TLDR
Overall, data from clinical trials seem to indicate that ACE inhibitors and possibly calcium antagonists should be preferred in the treatment of patients with diabetic and nondiabetic nephropathies.
Pathophysiology of Hypertensive Renal Damage: Implications for Therapy
TLDR
A critical evaluation of the clinical data suggests that the BP-independent renoprotection by RAS blockade has been overemphasized and that achieving lower BP targets is more important than the selection of antihypertensive regimens.
Long-term renal consequences of hypertension for normal and diseased kidneys
TLDR
Prevention of hypertension-induced barotrauma will require blood pressure to be reduced well into the normotensive range in patients with diabetes or chronic renal disease, as is being recognized in the currently recommended blood pressure goals.
Nephroprotective effect of antihypertensive drugs in essential hypertension
TLDR
Results of a number of studies evaluating nephroprotective effects of various drugs and regimens have indicated that certain agents, most notably angiotensin converting enzyme inhibitors and their combination with calcium antagonists, afford more protection than do others at similar levels of reduction of arterial pressure.
Blood Pressure Control and Nephroprotection in Diabetes
TLDR
It is unfortunate that only 11% of people being treated for hypertension with diabetic kidney disease achieve the blood pressure goal of < 130 mmHg, likely contributing to the climbing incidence of people starting dialysis.
Renal protective potential of antihypertensive drugs
  • D. Sušić
  • Medicine
    Expert opinion on investigational drugs
  • 2000
TLDR
Evidence is presented to show that in addition to renoprotection offered by reduction in arterial pressure, some antihypertensive agents may give more nephroprotection.
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
TLDR
Angiotensin-converting enzyme inhibitors appear to be more effective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline in hypertension.
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
TLDR
Albuminuria is the predominant renal risk marker in patients with type 2 diabetic nephropathy on conventional treatment; the higher the albuminuria, the greater the renal risk and the stronger the renal protection.
Blood Pressure Control, Proteinuria, and the Progression of Renal Disease
TLDR
The MDRD Study compared the rates of decline in glomerular filtration rate in 840 patients with a diverse array of renal diseases who were randomly assigned to either a usual or a low blood pressure goal and evaluated the effect of blood pressure on changes in proteinuria.
Calcium-channel blockers and the progression of renal disease
TLDR
The data indicate that there are probably important and clinically relevant differences between the classes of CCBs, with the dihydropyridine (DHP) CCBs most likely to have consistent deleterious effects on renal autoregulation.
...
1
2
3
4
5
...